GlaxoSmithKline (United States)

In vitro activity of gepotidacin against baseline Neisseria gonorrhoeae phenotypes and genotypes recovered from a clinical trial for uncomplicated urogenital gonorrhea (EAGLE-1)

ABSTRACT There is an urgent need for novel antimicrobials to treat multidrug-resistant strains of Neisseria gonorrhoeae . In a phase III trial (EAGLE-1), gepotidacin, a first-in-class triazaacenaphthylene antibacterial, demonstrated non-inferiority to ceftriaxone plus azithromyci...

Unravelling the Itch: Cross‐Sectional Analysis of Pruritus Patterns in the PicnicHealth Primary Biliary Cholangitis Registry

BACKGROUND & AIMS: Pruritus in primary biliary cholangitis (PBC) worsens patients' health-related quality of life (HRQoL). Serum alkaline phosphatase (ALP), a biomarker of PBC activity, has an unclear relationship with pruritus severity. METHODS: This retrospective, cross-section...

When Empiric Therapy Fails: Clinical and Economic Consequences in uUTIs Among US Women

Uncomplicated urinary tract infection (uUTI) management is increasingly challenging due to antibiotic treatment failure (TF). This retrospective, observational cohort study used Optum’s de-identified Electronic Health Record dataset (January 2017–September 2022) to investigate th...

The outpatient economic burden of respiratory syncytial virus infection in adults aged ≥ 60 years in Germany: results from the BUCOSS study

Abstract Background Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI) in adults aged ≥ 60 years, but data on its outpatient epidemiology and societal costs remain limited. Methods BUCOSS was a prospective observational study conducted over 3...

Bepirovirsen induces innate immune proteins independent of HBV

BACKGROUND: Bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus (HBV) mRNAs, is in development for the treatment of chronic HBV infection. Clinical studies have demonstrated that bepirovirsen has multiple mechanisms of action, including lowering HBV DNA,...